KWKyle M. Walsh

Kyle M. Walsh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kyle M. Walsh has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Joseph L. Wiemels

    Center for Genetic Epidemiology, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA, USA; Division of Pediatric Hematology/Oncology, Duke University Medical Center, Durham, NC, USA

    33 shared publications
  • Catherine Metayer

    School of Public Health, University of California, Berkeley, Berkeley, CA, USA; Division of Pediatric Hematology/Oncology, Duke University Medical Center, Durham, NC, USA

    28 shared publications
  • Quinn T. Ostrom

    Central Brain Tumor Registry of the United States, Hinsdale, IL, USA

    27 shared publications
  • Courtney Elise. Wimberly

    Department of Neurosurgery and Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine

    24 shared publications
  • Jill S. Barnholtz Sloan

    National Cancer Institute, Bethesda, USA

    24 shared publications
  • Helen M. Hansen

    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA; Division of Pediatric Hematology/Oncology, Duke University Medical Center, Durham, NC, USA

    23 shared publications

Latest Publications

  • The Key LARGO study: Building an international resource for glioblastoma epidemiology

    by Courtney E Wimberly, Michael C Brown, Kyle M Walsh, Quinn T Ostrom

    Background: Despite decades of epidemiologic research, no glioblastoma risk factors have been identified that explain substantial risk. Prior studies often rely on single- or multi-center recruitment, which is costly and limits generalizability. To address this and increase the diversity of glioblastoma patients in epidemiological research, we have launched the Key LARGO study (NCT06625684, Key Longitudinal Associations with Risk and Glioblastoma Outcomes), an ongoing observational study of glioblastoma patients and their caregivers. Methods: Key LARGO uses web-based enrollment and at-home biospecimen collection via mailed Tasso+ kits for self-collection of blood and serum. Participants complete a detailed, online survey (available in English or Spanish) on life history and health-related quality of life. Primary caregivers are enrolled to help report patient outcomes, including vital status. Results: Recruitment began on December 10, 2024. As of February 28, 2026, 114 patients and 52 caregivers have consented. Of these, 96 consented to blood collection, 73 received kits, and 52 have returned samples. Eighty-two participants completed the full study survey. Participants were 53% male, with a median age of 54 years (range 24-69) at the time of diagnosis. Diagnoses occurred between 2007 and 2025. Most (96%) identified as White. Seven percent identified as Hispanic or Latino. Blood collection kits have been returned from the United States, Canada, Croatia, Italy, Indonesia, and the United Kingdom. Conclusions: Key LARGO supports the feasibility of web-based recruitment and remote biospecimen collection in glioblastoma research. The current cohort is best suited for descriptive and hypothesis-generating analyses pending clinical/molecular validation and targeted recruitment.

  • Open Access

    Relationship between genetically determined telomere length and childhood glioma risk

    by Naying Zhou, Shaobo Li, Jon Foss-Skiftesvik, Anna M. Dahlin, Jonas Bybjerg-Grauholm, Beatrice Melin, Adam J. de Smith, Kyle M. Walsh, Joseph L. Wiemels

    While longer genetically predicted leukocyte telomere length (LTL) has been linked to increased glioma risk in adults, this association has not been investigated in pediatric populations. In this study, we applied Mendelian randomization (MR) and polygenic risk score (PRS) analyses to investigate the relationship between LTL and pediatric glioma risk, using 4,069 cases and 8,778 controls from the largest available childhood glioma meta-GWAS. Results suggested longer genetically predicted LTL was significantly associated with increased childhood glioma risk, with OR per 1 standard deviation increase in LTL of 2.12 (95% CI 1.32–3.39, P = .002) in the multi-ancestry group and 2.16 (95% CI 1.16–4.03; P = .015) in the European group. Key SNPs contributing to risk of childhood glioma included rs59294613 ( POT1 ), rs8105767 ( ZNF208 ), and rs7705526 ( TERT ), which differed from the top variants previously identified in adult glioma using the same genetic instruments. Age-stratified MR revealed a stronger association in children diagnosed after the age of 6 (OR = 1.89; P < .001) vs. ≤ 6 years (OR = 1.04; P = .732; P het = .006). PRS analysis further supported this age-stratified findings by demonstrating a positive association between LTL PRS and age at glioma diagnosis, particularly within age 0–10. This trend suggests a progressively greater influence of LTL on glioma risk in older children compared to younger children. In conclusion, this study provides the first genetic evidence linking longer genetically predicted LTL to increased pediatric glioma risk. While overall consistent with adult findings, distinct single-SNP associations, and age-dependent effects highlight unique biological mechanisms in children with glioma, warranting further direct investigation into telomere dynamics in early-life gliomagenesis.

  • Open Access

    Gabapentin repurposing for glioblastoma therapy: Real-world data analyses augmented by use of active comparators

    by Christine Ann Pittman Ballard, Kevin M. Goff, Mallika P. Patel, Kyle M. Walsh, Michelle Monje, Quinn T. Ostrom

    Glioblastoma ‘hijacks’ neuronal pathways to drive tumor growth, and drugs affecting the function of these pathways may potentiate survival gains. Recent studies have suggested clinical benefits with post-diagnostic use of gabapentin. We assessed the impact of taking gabapentin after glioblastoma diagnosis utilizing an active comparator model in a population-based dataset of older adults in the United States. We leveraged a cohort of glioblastoma patients >65 years old who received resection, radiation, and temozolomide from the Surveillance, Epidemiology and End Results data paired with Medicare claims. Those receiving post-diagnostic gabapentin (TMZ+G) were compared to those receiving standard of care treatment only (TMZ), and two active comparators (duloxetine [TMZ+D], and levetiracetam [TMZ+L]). Association between medication use and overall survival was assessed using cox proportional hazards models adjusted for known prognostic factors. Out of 2,494 individuals, 797 (32%) received TMZ, 146 (5.9%) received TMZ+G, 38 (1.5%) received TMZ+D, and 1,513 (60.7%) received TMZ+L. Median survival among those receiving TMZ (10 months) as compared to all other groups (TMZ+G=16.3 months, TMZ+D=16 months; TMZ+L=13.0 months). TMZ+G was associated with 47% decrease in hazard of death (p<0.001) compared to TMZ, and a 32% decrease (p<0.001) compared to TMZ+L. Women had a 43% decrease in hazard of death (p<0.001) in TMZ+G as compared to TMZ+L, while this difference was non-significant in men (p=0.204). These results show survival benefit associated with gabapentin and supports ongoing work therapeutically targeting neuron-glioma interactions.

  • Counting what counts: Registry completeness and the epidemiology of nonmalignant meningioma

    by Kyle M. Walsh

    Comprehensive and standardized registry capture of nonmalignant meningioma diagnoses is essential for valid surveillance and reliable epidemiologic research. Efforts to integrate radiographic diagnoses and richer tumor‐level detail will help discriminate risk factors from case ascertainment biases, which would strengthen both surveillance and etiologic inference.


  • Open Access

    Figure S1 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

    by Corey Neff, Mackenzie Price, Christine Ann Pittman Ballard, Gino Cioffi, Zhen Liu, Rabina Walsh, Jill S. Barnholtz-Sloan, Kyle M. Walsh, April K.S. Salama, Carey K. Anders, et al.

    Figure S1 illustrates the data filtering process used to build the analytic dataset

  • Open Access

    Table S4 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

    by Corey Neff, Mackenzie Price, Christine Ann Pittman Ballard, Gino Cioffi, Zhen Liu, Rabina Walsh, Jill S. Barnholtz-Sloan, Kyle M. Walsh, April K.S. Salama, Carey K. Anders, et al.

    Table S4 provides results from univariate survival and cumulative incidence analyses

  • Open Access

    Figure S3 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

    by Corey Neff, Mackenzie Price, Christine Ann Pittman Ballard, Gino Cioffi, Zhen Liu, Rabina Walsh, Jill S. Barnholtz-Sloan, Kyle M. Walsh, April K.S. Salama, Carey K. Anders, et al.

    Figure S3 shows association between atopic traits and treatment choice

  • Open Access

    Table S1 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

    by Corey Neff, Mackenzie Price, Christine Ann Pittman Ballard, Gino Cioffi, Zhen Liu, Rabina Walsh, Jill S. Barnholtz-Sloan, Kyle M. Walsh, April K.S. Salama, Carey K. Anders, et al.

    Table S1 shows codes used to classify atopic disease types

  • Open Access

    Data from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

    by Corey Neff, Mackenzie Price, Christine Ann Pittman Ballard, Gino Cioffi, Zhen Liu, Rabina Walsh, Jill S. Barnholtz-Sloan, Kyle M. Walsh, April K.S. Salama, Carey K. Anders, et al.

    Background:Development of new melanoma therapies has increased survival, and more patients are living to develop brain metastasis (BrM). Identifying those at increased risk of BrM is of significant public health importance, and our objective was to assess the relationship between atopy and survival or reduced BrM cumulative incidence (CI) in melanoma.Methods:This retrospective study was conducted in individuals (≥66 years) in linked Surveillance, Epidemiology, and End Results and Medicare data. History of atopy diagnosed prior to melanoma was ascertained using International Classification of Diseases-9/10 codes. Associations between atopy, CI of BrM, and overall survival were assessed using cox proportional hazards models to estimate hazard ratios and P values.Results:A total of 23,508 cutaneous melanoma cases were identified. Overall, 6.1% developed BrM, and 38% had history of atopy. Atopy was associated with an 18% decrease in death (P < 0.001). Among those without metastasis at diagnosis, atopy decreased BrM CI by 16% (P = 0.006). Among those with metastasis at diagnosis (any site), only those who received checkpoint inhibitors had a suggestive but nonsignificant survival with atopy.Conclusions:Atopy confers improved survival and decreased BrM CI. History of atopy in the elderly may identify those with more robust immune function that may be more responsive to treatment.Impact:Elderly individuals with prior diagnosis of atopy had significantly improved survival and decreased incidence of BrM as compared with individuals without atopy. This suggests that history of atopy may identify a subgroup within melanoma with improved response to treatment and a more robust immune system.